A host of studies have now convincingly demonstrated that targeting PKC θ could be a viable therapeutic strategy to block the T cell inflammatory response in autoimmunity, allergy, and allograft rejection (Marsland and Kopf, 2008; Zanin-Zhorov et al., 2011; Altman and Kong, 2012). The gene discussed is PRRT2; the disease is Autoimmunity.